Bypassing human CoQ10 deficiency.
Mol Genet Metab
; 123(3): 289-291, 2018 03.
Article
in En
| MEDLINE
| ID: mdl-29246431
ABSTRACT
Primary disorders of the human coenzyme Q10 (CoQ10) biosynthesis pathway are a known cause of severe pediatric diseases. So far, oral administration of CoQ10 is the only treatment strategy for affected individuals. However, the real benefit of CoQ10 supplementation remains questionable and clinical studies regarding efficiency are lacking. Here we provide an outlook on novel treatment approaches using CoQ precursor compounds. These metabolic bypass strategies might be a promising alternative for oral CoQ10 supplementation regimens.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Ataxia
/
Ubiquinone
/
Muscle Weakness
/
Mitochondrial Diseases
/
Hydroxybenzoates
Limits:
Animals
/
Humans
Language:
En
Journal:
Mol Genet Metab
Journal subject:
BIOLOGIA MOLECULAR
/
BIOQUIMICA
/
METABOLISMO
Year:
2018
Type:
Article
Affiliation country:
Germany